Abstract
The amino acid L-glutamate is generally recognized as the major excitatory neurotransmitter of the mammalian central nervous system (CNS) and glutamate receptors play a major role in fast excitatory synaptic transmission. Nmethyl- D-aspartate (NMDA)-type glutamate receptors are widely distributed throughout the CNS and operate ligandactivated ion channels. The activation and function of NMDA receptors are modulated by a variety of endogenous and exogenous compounds. Various anesthetic protocols have been used in pediatric medicine for many years in the absence of clear systematic assessment concerning drug exposure and possible adverse effects. It is known that most of the currently used anesthetic drugs have either NMDA receptor blocking or gamma-amino butyric acid (GABA) receptor activating properties. It has been reported that anesthetics such as ketamine, an NMDA receptor antagonist, cause neuronal cell death in rodents when administered during critical periods of development. The window of vulnerability to the neuronal effects of pediatric anesthetics seems to be restricted to the period of rapid synaptogenesis, also known as the brain growth-spurt period. Accentuated neurodegenerative mechanisms in the immature brain can thus increase neuronal susceptibility to exposure to anesthetic agents. Anesthetics that block NMDA or activate GABA receptors consistently increase cell death in the neonatal brain, suggesting that the physiological stimulation of NMDA receptors is necessary for normal neuronal synaptogenesis, differentiation, and survival during development. The main purposes of this review are to outline progress in the application of pharmacogenomic/systems approaches and animal models to systematically evaluate dose-response and time-course effects of anesthetic agents; to describe what is known about underlying mechanisms; and to define the relationship between altered NMDA receptor expression and the potential of anesthetics to cause toxicity during development. It should be mentioned that much of this discussion is based on experiments conducted only with ketamine. This is due in part to the use of ketamine in critical early studies and the volume of preclinical experimental work performed with this agent, and because comparative (rodent and nonhuman primates) data exist for this compound. The findings of the ketamine studies to date are sufficiently strong enough to cause concern for other agents which affect the same receptors.
Keywords: Glutamate neurotransmission, anesthetic agent, neurodegeneration
Central Nervous System Agents in Medicinal Chemistry
Title: Ketamine and Glutamate Receptors: Potential Toxicity of General Anesthetics during Rapid Brain Development
Volume: 8 Issue: 2
Author(s): Cheng Wang, Xuan Zhang, Xiaoju Zou, Merle G. Paule and William Slikker Jr.
Affiliation:
Keywords: Glutamate neurotransmission, anesthetic agent, neurodegeneration
Abstract: The amino acid L-glutamate is generally recognized as the major excitatory neurotransmitter of the mammalian central nervous system (CNS) and glutamate receptors play a major role in fast excitatory synaptic transmission. Nmethyl- D-aspartate (NMDA)-type glutamate receptors are widely distributed throughout the CNS and operate ligandactivated ion channels. The activation and function of NMDA receptors are modulated by a variety of endogenous and exogenous compounds. Various anesthetic protocols have been used in pediatric medicine for many years in the absence of clear systematic assessment concerning drug exposure and possible adverse effects. It is known that most of the currently used anesthetic drugs have either NMDA receptor blocking or gamma-amino butyric acid (GABA) receptor activating properties. It has been reported that anesthetics such as ketamine, an NMDA receptor antagonist, cause neuronal cell death in rodents when administered during critical periods of development. The window of vulnerability to the neuronal effects of pediatric anesthetics seems to be restricted to the period of rapid synaptogenesis, also known as the brain growth-spurt period. Accentuated neurodegenerative mechanisms in the immature brain can thus increase neuronal susceptibility to exposure to anesthetic agents. Anesthetics that block NMDA or activate GABA receptors consistently increase cell death in the neonatal brain, suggesting that the physiological stimulation of NMDA receptors is necessary for normal neuronal synaptogenesis, differentiation, and survival during development. The main purposes of this review are to outline progress in the application of pharmacogenomic/systems approaches and animal models to systematically evaluate dose-response and time-course effects of anesthetic agents; to describe what is known about underlying mechanisms; and to define the relationship between altered NMDA receptor expression and the potential of anesthetics to cause toxicity during development. It should be mentioned that much of this discussion is based on experiments conducted only with ketamine. This is due in part to the use of ketamine in critical early studies and the volume of preclinical experimental work performed with this agent, and because comparative (rodent and nonhuman primates) data exist for this compound. The findings of the ketamine studies to date are sufficiently strong enough to cause concern for other agents which affect the same receptors.
Export Options
About this article
Cite this article as:
Wang Cheng, Zhang Xuan, Zou Xiaoju, Paule G. Merle and Jr. Slikker William, Ketamine and Glutamate Receptors: Potential Toxicity of General Anesthetics during Rapid Brain Development, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/187152408784533914
DOI https://dx.doi.org/10.2174/187152408784533914 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Evidence of 2 Populations of Mephedrone Abusers by Hair Testing. Application to 4 Forensic Expertises
Current Neuropharmacology Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update
Current Medicinal Chemistry Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology Cingulate Volume Abnormalities in Emerging Psychosis
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Dopamine Transporter Ligands: Recent Developments and Therapeutic Potential
Current Topics in Medicinal Chemistry Assessment of Short- and Long-Term Outcomes of Patients Hospitalized With Intracerebral Hemorrhage
Current Neurovascular Research Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Potential Protective Effects of Cannabidiol on Neuroanatomical Alterations in Cannabis Users and Psychosis: A Critical Review
Current Pharmaceutical Design Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players
Current Topics in Medicinal Chemistry Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics Comparison of Two Molecular Scaffolds, 5-Methylisoxazole-3-Carboxamide and 5-Methylisoxazole-4-Carboxamide
Current Pharmaceutical Design Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Current Drug Discovery Technologies The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued)